New Age Alpha Advisors LLC Invests $177,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)

New Age Alpha Advisors LLC acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 3,520 shares of the biotechnology company's stock, valued at approximately $177,000.

Several other institutional investors have also modified their holdings of the company. Synergy Asset Management LLC boosted its holdings in Corcept Therapeutics by 131.3% during the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company's stock worth $22,369,000 after buying an additional 262,503 shares in the last quarter. Van ECK Associates Corp bought a new stake in shares of Corcept Therapeutics during the 4th quarter worth $4,483,000. State Street Corp grew its holdings in shares of Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock worth $162,871,000 after acquiring an additional 19,893 shares during the last quarter. Burney Co. raised its position in shares of Corcept Therapeutics by 9.1% during the fourth quarter. Burney Co. now owns 473,821 shares of the biotechnology company's stock worth $23,876,000 after purchasing an additional 39,657 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Corcept Therapeutics by 43.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,070 shares of the biotechnology company's stock valued at $11,712,000 after purchasing an additional 76,573 shares during the period. Institutional investors and hedge funds own 93.61% of the company's stock.

Insiders Place Their Bets

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sean Maduck sold 100,000 shares of Corcept Therapeutics stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $100.54, for a total value of $10,054,000.00. Following the completion of the transaction, the insider now owns 85,622 shares in the company, valued at $8,608,435.88. The trade was a 53.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 163,124 shares of company stock valued at $15,074,318 over the last 90 days. 20.50% of the stock is currently owned by company insiders.

Remove Ads

Corcept Therapeutics Stock Up 0.3 %

NASDAQ:CORT traded up $0.20 during trading hours on Monday, reaching $74.65. The company's stock had a trading volume of 2,559,365 shares, compared to its average volume of 1,105,142. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The company has a market cap of $7.88 billion, a price-to-earnings ratio of 59.25 and a beta of 0.15. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $117.33. The business's 50-day moving average is $65.10 and its 200-day moving average is $56.73.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. Equities research analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on CORT shares. Piper Sandler raised their target price on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a report on Thursday. Truist Financial lifted their price objective on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. HC Wainwright increased their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the company a "buy" rating in a report on Monday, March 31st. StockNews.com cut Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group upped their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $143.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.